Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride forward after quite a volatile year, better risk/reward is not enough to sway Deutsche Bank analyst Gregg Gilbert from the sidelines. What has left Gilbert cautiously optimistic on the company’s recovery, but dialing down his price target?